Abstracts Archive - Page 294 of 2607 - ACR Meeting Abstracts

Abstract Number: 1095 • ACR Convergence 2024
The Incidence of Gout Among Individuals with Hyperuricemia over Time – an Insight from a Nationwide Cohort Study
Shay Brikman¹, Amir Bieber², Liel Serfaty, MA³, Ran Abuhasira, MD, PhD⁴, Nadav Rappoport⁵ and Naomi Schlesinger⁶, ¹Emek Medical Center, Afula, Israel, ²Emek Medical Center, Clalit Health Services, Raanana, Israel, ³Department of Software and Information Systems Engineering, Ben-Gurion University of the Negev, Be'er Sheva, Israel, ⁴Clinical Research Center, Soroka University Medical Center, Be'er Sheva, Israel, ⁵Ben-Gurion University of the Negev, Beer-Sheva, Israel, ⁶University of Utah, Salt Lake City, UT
Background/Purpose: Hyperuricemia is considered the most important risk factor for developing Gout, the most common adult inflammatory arthritis. Hyperuricemia is defined by a serum urate…
Abstract Number: 1353 • ACR Convergence 2024
Association Between Frailty and Incident Cancer in Newly Diagnosed Rheumatoid Arthritis
Bhavik Bansal¹, Laura Gold², Katherine Wysham³, James Andrews⁴, Alexa Meara⁵, Carolyn Presley⁶, Elad Sharon⁷, Jiha Lee⁸, Jennifer Barton⁹, Una Makris¹⁰ and Namrata Singh¹¹, ¹All India Institute of Medical Sciences, New Delhi, Delhi, India, ²University of Washington, Seattle, ³VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵The Ohio State University Wexner Medical Center, COLUMBUS, OH, ⁶The Ohio State Medical Center, Columbus, OH, ⁷Dana Farber Cancer Institute, Boston, MA, ⁸University of Michigan, Ann Arbor, MI, ⁹VA Portland Health Care System/OHSU, Portland, OR, ¹⁰UT Southwestern Medical Center and Dallas VA, Dallas, TX, ¹¹University of Washington, Bellevue, WA
Background/Purpose: Rheumatoid Arthritis (RA) is associated with an increased risk of cancer, but the underlying risk factors remain poorly understood. Frailty is linked to an…
Abstract Number: 1617 • ACR Convergence 2024
Persistence of Imaging Abnormality in Patients with Large Vessel Vasculitis Despite Clinical Remission
Luigi Boiardi¹, Pierluigi Macchioni¹, Francesco Muratore², Chiara Marvisi¹, Caterina Ricordi¹, Annibale Versari¹, Giulia Besutti¹, Lucia Spaggiari¹, Stefania Croci¹ and Carlo Salvarani¹, ¹Azienda Sanitaria Locale, IRCSS, Reggio Emilia, Reggio Emilia, Italy, ²Unit of Rheumatology, Azienda USL - IRCCS di Reggio Emilia and University of Modena and Reggio Emilia, Reggio Emilia, Italy
Background/Purpose: Aim of our study was to evaluate the persistence of imaging abnormalities in patients with Takayasu (TAK) and large vessel giant cell arteritis (LV-GCA)…
Abstract Number: 1566 • ACR Convergence 2024
Comparative Analysis of Clinical Features and Outcomes in Late Onset vs. Early Onset Scleroderma Renal Crisis – A Multicenter Study
Sumbal Wajid¹, Lee Shapiro², Virginia Steen³, Robyn Domsic⁴, Paul J. Feustel⁵ and Swati Mehta⁶, ¹Albany Medical Center, Albany, NY, ²Division of Rheumatology, Department of Medicine, Albany Medical Center, Albany, NY, ³Georgetown University School of Medicine, Washington, DC, ⁴Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ⁵Department of Neuroscience and Experimental Therapeutics, Albany Medical Center, Albany, NY, ⁶Division of Nephrology, Department of Medicine, Albany Medical Center, Albany, NY
Background/Purpose: Scleroderma renal crisis (SRC) is a life-threatening complication of systemic sclerosis (SSc), historically described to occur within the first 5 years of SSc diagnosis.…
Abstract Number: 1598 • ACR Convergence 2024
Projecting the Impact of Standard, Reduced-Dose, and Minimal-Dose Glucocorticoid Regimens in the Treatment of ANCA-Associated Vasculitis Using Simulation Modeling
Naomi Patel¹, Aaron Wu¹, Shruthi Srivatsan¹, Eli Miloslavsky², Peter Merkel³, John Stone⁴, Hyon K. Choi⁵, Emily Hyle¹ and Zachary Wallace², ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Newton, MA, ³University of Pennsylvania, Philadelphia, PA, ⁴Massachusetts General Hospital , Harvard Medical School, Concord, MA, ⁵Massachusetts General Hospital, Lexington, MA
Background/Purpose: Glucocorticoids (GCs) remain a cornerstone of treatment of ANCA-associated vasculitis (AAV) but predispose people to infectious, metabolic, and other toxicities. We projected the long-term…
Abstract Number: 1613 • ACR Convergence 2024
Adherence to Dietary Recommendations and the Risk of Developing Giant Cell Arteritis; A Nested Case-Control Study
Poi Kwanyuen¹, Karin Wadström¹, Emily Sonestedt¹, Charlotta Fors¹, Rebecka Bäcklund¹, Aladdin Mohammad², Lennart TH Jacobsson¹ and Carl Turesson¹, ¹Lund University, Malmö, Sweden, ²Lund University, Lund, Sweden
Background/Purpose: Giant cell arteritis (GCA) affects large and medium-sized vessels in elderly individuals. Previous studies have reported associations with lower body mass index and lower…
Abstract Number: 1508 • ACR Convergence 2024
Clinical Characteristics and Prognosis of Late-onset Systemic Lupus Erythematosus in 305 Japanese Patients
Yuko Shirota¹, Misa Oguma², Ryo Kuwata³, Yumi Tajima⁴, Yumiko Oka⁵, Miki Takeshita², Takao Kodera² and Tomonori Ishii², ¹Tohoku University Hospital / Department of Hematology and Rheumatology, Sendai, Japan, ²Tohoku Medical and Pharmaceutical University / Department of Hematology and Rheumatology, Sendai, Japan, ³National Center for Global Health and Medicine / Division of Rheumatic Diseases, Shinjyuku, Tokyo, Japan, ⁴Tohoku Medical and Pharmaceutical University / Department of Hematology and Rheumatology, Sendai, Miyazaki, Japan, ⁵Tohoku Medical and Pharmaceutical University / Department of Hematology and Rheumatology, Sendai
Background/Purpose: In recent years, the number of older patients with systemic lupus erythematosus (SLE) in Japan has been increasing, with particular attention to those developing…
Abstract Number: 1577 • ACR Convergence 2024
Elevated Neutrophil Extracellular Traps in Systemic Sclerosis-associated Vasculopathy and Suppression by a Synthetic Prostacyclin Analog
Neda Kortam¹, Wenying Liang¹, Claire Shiple¹, Suiyuan Huang¹, Rosemary Gedert¹, James St. Clair¹, Cyrus Sarosh², Caroline Foster¹, Eliza Pei-Suen Tsou¹, John Varga¹, Jason Knight¹, Dinesh Khanna¹ and Ramadan Ali¹, ¹University of Michigan, Ann Arbor, MI, ²University of Michigan, Temperance, MI
Background/Purpose: Neutrophils and neutrophil extracellular traps (NETs) contribute to the vascular complications of multiple diseases, but their role in systemic sclerosis (SSc) is understudied. We…
Abstract Number: 1490 • ACR Convergence 2024
Multi-centered Clinical Validation of T Cell-bound C4d (TC4d) and T Cell Autoantibodies (TIgG and TIgM): Sensitive and Specific Biomarkers of SLE with Enhanced Accuracy Compared to Conventional SLE Tests
Vasileios Kyttaris¹, Andrew Concoff², Touba Warsi³, Sepehr Taghavi³, Sudha Kumar³, Stanley Park³, Abigail Patalinghug³, Christine Schleif³, Brittany Partain⁴, Joseph Ahearn⁵, Nicole Wilson⁶, Chau-Ching Liu⁶, Susan Manzi⁶ and Tyler O'Malley⁷, ¹BIDMC, Boston, MA, ²Exagen, Inc., Los Angeles, CA, ³Exagen, Carlsbad, CA, ⁴Exagen, Boston, MA, ⁵Allegheny Health Network, Wexford, PA, ⁶Allegheny Health Network, Pittsburgh, PA, ⁷Exagen, Vista, CA
Background/Purpose: Conventional SLE diagnostic markers lack sensitivity and are biased towards severe disease, resulting in a subset of clinically ambiguous ANA-positive but specific autoantibody-negative patients.…
Abstract Number: 1609 • ACR Convergence 2024
Characteristics of a Cohort of Patients with Interstitial Lung Disease and ANCA Positivity in a University Hospital
Cristina Valero¹, Claudia Valenzuela², Elisa Martínez-Besteiro³, Patricia Quiroga Colina⁴, Arantzazu Alfranca⁵, Esther Vicente-rabaneda⁶, Santos Castañeda⁶ and Rosario García-Vicuña⁷, ¹Hospital de la Princesa, Madrid, Spain, ²ILD Unit, Pulmonology Department, Hospital Universitario de la Princesa, University Autonomade Madrid, Madrid, Spain, Madrid, Madrid, Spain, ³Pulmonology Service, Hospital Universitario de la Princesa, IIS-Princesa, Madrid, Spain, Madrid, Madrid, Spain, ⁴Division of Rheumatology, Hospital Universitario de La Princesa, Madrid, Spain, ⁵Immunology Service, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, Madrid, Madrid, Spain, ⁶Hospital Universitario de La Princesa, Madrid, Spain, ⁷Hospital Universitario de la Princesa, Madrid, Madrid, Spain
Background/Purpose: The prevalence of ANCA positivity at diagnosis of interstitial lung disease (ILD) ranges between 4-36% for anti-MPO and 2-4% for anti-PR3. ILD is more…
Abstract Number: 1505 • ACR Convergence 2024
Incidence of Cardiovascular and Venous Thromboembolic Events in Four Autoantibody-defined Systemic Lupus Erythematosus Clusters
Sara Ferrigno¹, Elizabeth Arkema², Lina Marcela Diaz-Gallo³, Iva Gunnarsson⁴, Agneta Zickert⁴ and Elisabet Svenungsson⁵, ¹Department of Systems' Medicine, University of Rome Tor Vergata, Rome, Italy, ²Department of Medicine Solna, Clinical Epidemiology Division, Stockholm, Sweden, ³Center for Molecular Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ⁴Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ⁵Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Systemic lupus erythematosus (SLE) patients have higher cardiovascular (CV) risk compared to the general population, with a standardized CV mortality rate of 2-3 and…
Abstract Number: 1611 • ACR Convergence 2024
Impact of Mepolizumab on Patient-reported Outcomes in Eosinophilic Granulomatosis with Polyangiitis by Using the ANCA-associated Vasculitis Patient-reported Outcomes (AAV-PRO) Questionnaire: A European Multicentre Prospective Study
Paolo Delvino¹, Luca Quartuccio², Joanna Robson³, Federico Alberici⁴, Diego Bagnasco⁵, Alvise Berti⁶, Marco Caminati⁷, Marta Camoni⁸, Maria Cid⁹, Edoardo Conticini¹⁰, Giulia Costanzo¹¹, Claire de Moreuil¹², Stefano Del Giacco¹¹, Georgina Espigol-Frigole¹³, Virginia V Ferretti¹⁴, Franco Franceschini¹⁵, Luca Iorio¹⁶, Anna Kernder¹⁷, Catherine Klersy¹⁴, Alberto Lo Gullo¹⁸, Laura Losappio¹⁹, Elena Manna²⁰, Matteo Maule²¹, Carlomaurizio Montecucco²², Negrini Simone²³, Roberto Padoan²⁴, Francesca Regola²⁵, Luisa Ricciardi²⁶, Jan Schroeder¹⁹, Benjamin Terrier²⁷, Paola Toniati²⁸, Elena Treppo², Maria-Letizia Urban²⁹, Augusto Vaglio³⁰, Giacomo Emmi³¹ and Sara Monti³², and European EGPA Study Group, ¹University of Milano-Bicocca, Milan, Milan, Italy, ²Division of Rheumatology, Department of Medicine (DMED), University of Udine, Udine, Italy, Udine, Italy, ³UWE Bristol, Bristol, United Kingdom, ⁴Nephrology Unit, University of Brescia, ASST Spedali Civili, University of Brescia, Brescia, Italy, Brescia, Italy, ⁵Allergy and Respiratory Diseases, Department of Internal Medicine (DIMI), IRCCS Policlinico San Martino, Genoa, Italy, ⁶University of Trento, Rochester, Italy, ⁷Department of Medicine, Asthma, Allergy and Clinical Immunology Section, University of Verona, Verona, Italy, ⁸Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy, ⁹Hospital Clinic Barcelona. University of Barcelona, Barcelona, Spain, ¹⁰University of Siena, Siena, Siena, Italy, ¹¹Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy, ¹²Service de médecine interne, CHU de Brest, Brest, France, ¹³Hospital Clinic de Barcelona, Barcelona, Spain, ¹⁴Biostatistcs & Clinical Trial Center, Fondazione IRCCS Policlinico San Matteo, Pavia, Pavia, Italy, ¹⁵Scleroderma Unit, Rheumatology and Clinical Immunology Unit, ERN ReCONNET, ASST Spedali Civili, Brescia, Italy, Brescia, Italy, ¹⁶Rheumatology Unit, Department of Medicine DIMED, University of Padua, Padova, Italy, Padova, Italy, ¹⁷HHU Dusseldorf, Dusseldorf, Germany, ¹⁸Rheumatology Unit, Papardo Hospital, Messina, Italy, ¹⁹Division of Allergy and Clinical Immunology, ASST GOM Niguarda, Milan, Milan, Italy, ²⁰Division of Rheumatology, Fondazione IRCCS Policlinico San Matteo, Pavia, Pavia, Italy, ²¹Asthma Center and Allergy Unit, Verona Integrated University Hospital, Verona, Verona, Italy, ²²IRCCS policlinico S. Matteo foundation, University of Pavia, Pavia, Italy, ²³Department of Internal Medicine (DIMI), University of Genoa, Genoa, Genoa, Italy, ²⁴Department of Medicine DIMED, Division of Rheumatology, University of Padua, Padua, Italy, ²⁵Unit of Rheumatology and Clinical Immunology, ASST Spedali Civili Brescia and University of Brescia, Brescia, Italy, ²⁶Allergy and Immunology Unit, Department of Clinical and Experimental Medicine, G. Martino Teaching Hospital, University of Messina, Messina, Messina, Italy, ²⁷Service de Médecine interne, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France, ²⁸Spedali civili, 25123, Italy, ²⁹Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, ³⁰Department of Biomedical, Experimental and Clinical Sciences "Mario Serio", University of Firenze, Florence, Italy, ³¹University of Trieste, Trieste, Italy, ³²IRCCS Istituto Auxologico Italiano, Milan, Italy
Background/Purpose: Mepolizumab (MEPO) proved its efficacy in the treatment of eosinophilic granulomatosis with polyangiitis (EGPA) in the randomized controlled MIRRA trial. The ANCA-associated vasculitis patient-reported…
Abstract Number: 1578 • ACR Convergence 2024
Association of Systemic Sclerosis and Other Systemic Autoimmune Disease Diagnosis with Increasing Anti-RNA Polymerase III Antibodies
Warren Balaja¹, Mashood Badshah² and Megan Krause³, ¹University of Kansas Medical Center, Kansas City, KS, ²The University of Kansas Medical Center, Kansas City, KS, ³University of Kansas, Kansas City, KS
Background/Purpose: Anti-RNA polymerase III antibody (ARA) is a disease-specific antibody important for the identification and stratification of varying phenotypes of systemic sclerosis (SSc). Previous studies…
Abstract Number: 1514 • ACR Convergence 2024
Immunosenescent and Exhausted T Cells in Patients with Systemic Lupus Erythematosus and Cognitive Impairment
Erik Cimé-Aké¹, Guadalupe Lima², Emilio G. Lazarini¹, Sandra Juárez³, Luis Llorente² and Hilda Fragoso-Loyo¹, ¹Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Immunology and Rheumatology Department, Mexico City, Mexico, ²Instituto Nacional de Ciencias Médicas y Nutrición. Salvador Zubirán. Immunology and Rheumatology Department, Mexico City, Mexico, ³Instituto Nacional de Ciencias Médicas y Nutrición. Salvador Zubirán. Neurology and Psychiatry Department, Mexico City, Mexico
Background/Purpose: Cognitive impairment (CI) in systemic lupus erythematosus (SLE) may result from a chronic pro-inflammatory state in which immunosenescent and exhausted T-lymphocytes could be involved.…
Abstract Number: 0581 • ACR Convergence 2024
Unmet Criteria for Achieving Minimal and Very Low Disease Activity Among Patients with Psoriatic Arthritis Initiating Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drugs in the CorEvitas PsA/SpA Registry
Alexis Ogdie¹, Chao Song², Nicole Middaugh³, Maya Marchese³, Melissa Eliot³, Robert Low² and Philip Mease⁴, ¹Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²UCB Pharma, Smyrna, GA, ³CorEvitas, LLC, Waltham, MA, ⁴Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA
Background/Purpose: Minimal disease activity (MDA) is associated with reduced radiographic progression and improved quality of life among patients (pts) with PsA.1 Clinical advances made MDA…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].